A common bacterium best known for causing pneumonia and sinus infections may also play a surprising role in Alzheimer’s disease. Researchers found that Chlamydia pneumoniae can invade the retina and brain, where it sparks inflammation, nerve cell death, and the buildup of amyloid-beta—the hallmark protein linked to Alzheimer’s. Higher levels of the bacterium were found in people with Alzheimer’s,
Regulators say Ohio hospital system made it difficult for health insurers to offer cheaper plans.
In an effort to battle against what members feel is an existential threat to their businesses, a group of 10 domestic biotech companies has launched the Midsized Biotech Alliance of America with a focus on contesting the Trump administration’s Most Favored Nation drug pricing policy.
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
And other biotech news brought to you by The Readout newsletter
The FDA's top drug regulator indicated in her first address to staff that she will scrutinize antidepressants and shots used to protect babies from RSV
Catalent is cutting more roles at its gene therapy manufacturing facility in Harmans, Maryland. This round of layoffs will affect 93 employees at the Harmans facility and three more in nearby Baltimore.
And other health news from today's Morning Rounds newsletter
The new proposed board members come after an extraordinary general meeting last fall saw a significant change in leadership.
Gilead penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. A cell therapy company could end a one-year-plus biotech IPO drought in Tokyo. Novo Nordisk faces increased GLP-1 competition in China. And more.
After the pharmaceutical industry spent much of the past year safeguarding its businesses against the threat of U.S. import tariffs, a new Supreme Court ruling now waylays the Trump administration's trade agenda—at least in part.
Exercise may sharpen the mind by repairing the brain’s protective shield. Researchers found that physical activity prompts the liver to release an enzyme that removes a harmful protein causing the blood-brain barrier to become leaky with age. In older mice, dialing down this protein reduced inflammation and improved memory. The discovery points to a surprising body-to-brain pathway that could insp
AstraZeneca has secured a key regulatory win in its effort to reclaim the lead in the BTK inhibitor market, with the FDA approving its Calquence plus Venclexta as the first all-oral, fixed-duration regimen for first-line chronic lymphocytic leukemia.
After manufacturing the antibiotic Rocephin for four decades—and developing it into one of the company’s first blockbuster medicines—Roche is looking to divest the treatment and its production facility near its headquarters in Switzerland.
Joe Sachs, a physician and executive producer on “The Pitt,” and the CEO of Undue Medical Debt weigh in on the show’s foray into a health care crisis.
“We do not let pilots fly without instrument support simply because they technically could. Why should medicine be different?”
Would you trust AI to renew your drug prescriptions? Alex Hogan explores the question on this week's episode of STATus Report.
As smoking rates fall in the U.S., startups and influencers are pushing the purported cognitive and health benefits of indulging in nicotine.
A handful of states are considering initiatives to increase funding for scientific research as uncertainty around federal dollars has grown.
Novartis will transfer its 70.68% stake in Novartis India Limited—a Bombay Stock Exchange-listed company that primarily handles older and off-patent drugs in areas like immunology, neuroscience and pain—to a group of private equity firms.